DoW Bone Marrow Failure, Investigator-Initiated Research Award

This funding opportunity, titled "DoW Bone Marrow Failure, Investigator-Initiated Research Award" under solicitation HT942526BMFRPIIRA, is designed to advance research in bone marrow failure through investigator-driven projects that build on established discoveries and demonstrate potential for significant clinical impact. The award supports translational and preclinical studies, research involving human data or anatomical specimens, and correlative analyses linked to clinical trials, but explicitly excludes funding for full clinical trials. It also permits IND-enabling activities such as lead compound characterization, pharmacokinetic and toxicology assessments, and formulation development. Applications must include preliminary data and are limited to a total direct cost cap of $1,250,000 over a maximum performance period of three years, with awards anticipated by September 30, 2027. A unique feature of this mechanism is the allowance for a partnering Principal Investigator structure, where only the initiating PI submits a pre-application, but both PIs must submit full, coordinated applications; failure of either application results in the withdrawal of the entire project. The submission window opens on June 17, 2026, with a deadline of November 4, 2026, and applications must be submitted via eBRAP for intramural applicants or Grants.gov for extramural applicants. The proposal requires a comprehensive set of attachments, including a five-page Statement of Work, a three-page Transition Plan, one-page Limitations on Lay Abstract, Impact Statement, Translation Potential Statement, Research Team Statement, and Animal Research Plan, among others, all submitted as individual PDFs with strict page limits. Evaluation occurs through a two-tier peer and programmatic review process, with technical merit assessed equally across criteria such as research strategy, feasibility, impact, translation potential, and team qualifications, without assigned numerical weights. The Transition Plan must detail regulatory, commercialization, and funding pathways, while the Intellectual and Material Property Plan ensures clarity on ownership and use rights. All applicants must maintain an active SAM.gov registration with a UEI and comply with NSPM-33 foreign affiliation disclosures, GMP/GLP/GCP standards, and inclusion of women and minorities in relevant studies. Performance occurs at the applicant institutions, with no fixed location, and no procurement-specific line items or FOB terms apply, as this is a research grant administered under the Congressionally Directed Medical Research Programs by the Department of the Army’s USAMRAA, with funding contingent on fiscal availability through September